首页 > 最新文献

European Heart Journal - Quality of Care and Clinical Outcomes最新文献

英文 中文
Psychiatric morbidity and work participation in patients with congenital ventricular septal defects: a case-controlled study. 先天性室间隔缺损患者的精神病发病率和工作参与:病例对照研究。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcad072
Filip Eckerström, Vibeke Elisabeth Hjortdal, Charlotte Ulrikka Rask, Camilla Nyboe

Background: The burden of psychiatric morbidity, level of education, and work participation are currently unknown in patients with congenital ventricular septal defects (VSD).

Methods and results: In a Danish population-based cohort study using nationwide medical registries, the burden of psychiatric disorders, use of psychotropic agents, level of education, and work participation were examined in patients with isolated congenital VSD and controls from the general population matched by age and sex. Subjects with known chromosomal abnormalities were excluded. To compute estimates, Cox proportional regression model, Fine and Gray's competing risk regression, and Kaplan-Meier failure function were used. We included 8006 patients and 79 568 controls born before 2018. Median follow-up was 23 years. Compared with controls, patients with VSD displayed a hazard ratio (HR) of 1.24 [95% confidence interval (CI): 1.17-1.32] for any psychiatric disorder where the hazard for intellectual disabilities was most pronounced [HR of 3.66 (95% CI: 2.98-4.50)]. The use of psychotropic agents was higher in patients compared with controls [HR 1.14 (95% CI: 1.09-1.20)]. The work participation was lower in patients with VSD compared with controls (P < 0.001) and was lower in patients with VSD with a psychiatric disorder compared with those without (P < 0.001). The 40-year cumulative incidence of permanent social security benefits was 29% in patients with psychiatric disorders (vs. 21% in controls with psychiatric disorders) and 8% in patients without psychiatric disorders (vs. 4% in controls).

Conclusion: Patients with isolated VSD suffer from a higher burden of psychiatric disorders and display lower work participation compared with matched controls from the general Danish population. It is important to consider longer-term impacts on mental health, education, and subsequent employment in patients with VSD, in addition to cardiovascular effects, as these factors severely affect quality of life and have direct socioeconomic implications on an individual and societal level.

背景:目前尚不清楚先天性室间隔缺损(VSD)患者的精神疾病负担、教育水平和工作参与情况:方法:在一项以丹麦人口为基础的队列研究中,研究人员利用全国性的医疗登记资料,对孤立性先天性室间隔缺损患者以及年龄和性别相匹配的普通人群对照组的精神疾病负担、精神药物使用情况、教育水平和工作参与情况进行了调查。已知染色体异常的受试者被排除在外。在计算估计值时,使用了 Cox 比例回归模型、Fine 和 Gray 的竞争风险回归以及 Kaplan-Meier 失败函数:我们纳入了 2018 年前出生的 8006 名患者和 79568 名对照组。中位随访时间为 23 年。与对照组相比,VSD患者任何精神障碍的HR为1.24(95% CI:1.17-1.32),其中智力障碍的危险性最为明显[HR为3.66(95% CI:2.98-4.50)]。与对照组相比,患者使用精神药物的比例更高[HR 1.14(95% CI:1.09-1.20)]。与对照组相比,VSD 患者的工作参与率较低(P与丹麦普通人群中的匹配对照组相比,孤立 VSD 患者的精神障碍负担更重,工作参与度更低。除了心血管方面的影响外,考虑对 VSD 患者的心理健康、教育和后续就业的长期影响也很重要,因为这些因素严重影响生活质量,并对个人和社会产生直接的社会经济影响。
{"title":"Psychiatric morbidity and work participation in patients with congenital ventricular septal defects: a case-controlled study.","authors":"Filip Eckerström, Vibeke Elisabeth Hjortdal, Charlotte Ulrikka Rask, Camilla Nyboe","doi":"10.1093/ehjqcco/qcad072","DOIUrl":"10.1093/ehjqcco/qcad072","url":null,"abstract":"<p><strong>Background: </strong>The burden of psychiatric morbidity, level of education, and work participation are currently unknown in patients with congenital ventricular septal defects (VSD).</p><p><strong>Methods and results: </strong>In a Danish population-based cohort study using nationwide medical registries, the burden of psychiatric disorders, use of psychotropic agents, level of education, and work participation were examined in patients with isolated congenital VSD and controls from the general population matched by age and sex. Subjects with known chromosomal abnormalities were excluded. To compute estimates, Cox proportional regression model, Fine and Gray's competing risk regression, and Kaplan-Meier failure function were used. We included 8006 patients and 79 568 controls born before 2018. Median follow-up was 23 years. Compared with controls, patients with VSD displayed a hazard ratio (HR) of 1.24 [95% confidence interval (CI): 1.17-1.32] for any psychiatric disorder where the hazard for intellectual disabilities was most pronounced [HR of 3.66 (95% CI: 2.98-4.50)]. The use of psychotropic agents was higher in patients compared with controls [HR 1.14 (95% CI: 1.09-1.20)]. The work participation was lower in patients with VSD compared with controls (P < 0.001) and was lower in patients with VSD with a psychiatric disorder compared with those without (P < 0.001). The 40-year cumulative incidence of permanent social security benefits was 29% in patients with psychiatric disorders (vs. 21% in controls with psychiatric disorders) and 8% in patients without psychiatric disorders (vs. 4% in controls).</p><p><strong>Conclusion: </strong>Patients with isolated VSD suffer from a higher burden of psychiatric disorders and display lower work participation compared with matched controls from the general Danish population. It is important to consider longer-term impacts on mental health, education, and subsequent employment in patients with VSD, in addition to cardiovascular effects, as these factors severely affect quality of life and have direct socioeconomic implications on an individual and societal level.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of pharmacist-led interventions on the appropriateness and clinical outcomes of anticoagulant therapy: a systematic review and meta-analysis. 药剂师主导的干预对抗凝剂治疗的适当性和临床结果的影响:系统回顾和荟萃分析。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae045
Belayneh Kefale, Gregory M Peterson, Corinne Mirkazemi, Woldesellassie M Bezabhe

Aim: Although pharmacist-led interventions in anticoagulant (AC) therapy are widely accepted, there is a lack of evidence comparing their effectiveness with usual care in terms of AC therapy appropriateness and clinical outcomes. We aimed to estimate the comparative effectiveness of pharmacist-led interventions on the appropriateness and clinical outcomes of AC therapy.

Methods and results: Adhering to the PRISMA guidelines, we searched PubMed, EMBASE, and Scopus databases to identify randomized controlled trials and quasi-experimental and cohort studies published between 2010 and 2023. A random-effects model was used to calculate pooled intervention effects. We assessed heterogeneity (using Higgins' I2 and Cochran's Q) and publication bias (using Egger's test, the trim-and-fill method, and visualization of the funnel plot). In total, 35 studies involving 10 374 patients in the intervention groups and 11 840 in the control groups were included. The pharmacist-led interventions significantly improved the appropriateness of AC therapy [odds ratio (OR): 3.43, 95% confidence interval (CI): 2.33-5.06, P < 0.01]. They significantly decreased total bleeding [relative risk (RR): 0.75, 95% CI: 0.58-0.96, P = 0.03) and hospitalization or readmission (RR: 0.64, 95% CI: 0.41-0.99, P = 0.04). However, the impact of the pharmacist-led interventions on thromboembolic events (RR: 0.69, 95% CI: 0.46-1.02, P = 0.07) and mortality (RR: 0.76, 95% CI: 0.51-1.13, P = 0.17) was not significant.

Conclusion: Pharmacist-led interventions demonstrated superior outcomes in optimizing AC therapy compared with usual care. Further research is needed to evaluate pharmacist-led interventions' cost-effectiveness and long-term sustainability. PROSPERO registration number: CRD42023487362.

目的:尽管药剂师主导的抗凝治疗干预已被广泛接受,但在抗凝治疗的适当性和临床结果方面,缺乏将药剂师主导的干预与常规护理的有效性进行比较的证据。我们旨在估算药剂师主导的干预措施对抗凝血疗法的适宜性和临床结果的比较效果:根据 PRISMA 指南,我们检索了 PubMed、EMBASE 和 Scopus 数据库,以确定 2010 年至 2023 年间发表的随机对照试验、准实验研究和队列研究。我们采用随机效应模型计算干预效果。我们评估了异质性(使用 Higgins's I2 和 Cochran's Q)和发表偏倚(使用 Egger's 检验、修剪填充法和漏斗图可视化)。共纳入了 35 项研究,涉及干预组 10 374 名患者和对照组 11 840 名患者。药剂师指导的干预措施显著提高了 AC 治疗的适当性(几率比 [OR]:3.43;95% 置信区间 [CI]:2.33-5.06,P 结论:药剂师主导的干预措施明显改善了 AC 治疗的适宜性:与常规护理相比,药剂师指导的干预措施在优化 AC 治疗方面效果更佳。需要进一步开展研究,以评估药剂师指导的干预措施的成本效益和长期可持续性。
{"title":"The effect of pharmacist-led interventions on the appropriateness and clinical outcomes of anticoagulant therapy: a systematic review and meta-analysis.","authors":"Belayneh Kefale, Gregory M Peterson, Corinne Mirkazemi, Woldesellassie M Bezabhe","doi":"10.1093/ehjqcco/qcae045","DOIUrl":"10.1093/ehjqcco/qcae045","url":null,"abstract":"<p><strong>Aim: </strong>Although pharmacist-led interventions in anticoagulant (AC) therapy are widely accepted, there is a lack of evidence comparing their effectiveness with usual care in terms of AC therapy appropriateness and clinical outcomes. We aimed to estimate the comparative effectiveness of pharmacist-led interventions on the appropriateness and clinical outcomes of AC therapy.</p><p><strong>Methods and results: </strong>Adhering to the PRISMA guidelines, we searched PubMed, EMBASE, and Scopus databases to identify randomized controlled trials and quasi-experimental and cohort studies published between 2010 and 2023. A random-effects model was used to calculate pooled intervention effects. We assessed heterogeneity (using Higgins' I2 and Cochran's Q) and publication bias (using Egger's test, the trim-and-fill method, and visualization of the funnel plot). In total, 35 studies involving 10 374 patients in the intervention groups and 11 840 in the control groups were included. The pharmacist-led interventions significantly improved the appropriateness of AC therapy [odds ratio (OR): 3.43, 95% confidence interval (CI): 2.33-5.06, P < 0.01]. They significantly decreased total bleeding [relative risk (RR): 0.75, 95% CI: 0.58-0.96, P = 0.03) and hospitalization or readmission (RR: 0.64, 95% CI: 0.41-0.99, P = 0.04). However, the impact of the pharmacist-led interventions on thromboembolic events (RR: 0.69, 95% CI: 0.46-1.02, P = 0.07) and mortality (RR: 0.76, 95% CI: 0.51-1.13, P = 0.17) was not significant.</p><p><strong>Conclusion: </strong>Pharmacist-led interventions demonstrated superior outcomes in optimizing AC therapy compared with usual care. Further research is needed to evaluate pharmacist-led interventions' cost-effectiveness and long-term sustainability. PROSPERO registration number: CRD42023487362.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The beginning of wisdom is the definition of terms: counting heart failure hospitalizations. 智慧的开端是术语的定义:计算心力衰竭的住院次数。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae062
J J Cuthbert, A L Clark
{"title":"The beginning of wisdom is the definition of terms: counting heart failure hospitalizations.","authors":"J J Cuthbert, A L Clark","doi":"10.1093/ehjqcco/qcae062","DOIUrl":"10.1093/ehjqcco/qcae062","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced access to primary care for immigrants increases cardiovascular complications and hospital admissions: the importance of information and education. 移民获得初级保健的机会减少,增加了心血管并发症和入院率。信息和教育的重要性。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae042
Raimondo Gabriele, Immacolata Iannone, Antonio V Sterpetti
{"title":"Reduced access to primary care for immigrants increases cardiovascular complications and hospital admissions: the importance of information and education.","authors":"Raimondo Gabriele, Immacolata Iannone, Antonio V Sterpetti","doi":"10.1093/ehjqcco/qcae042","DOIUrl":"10.1093/ehjqcco/qcae042","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Italian Fabry Disease Cardiovascular Registry (IFDCR). 意大利法布里病心血管登记处(IFDCR)。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae052
Giuseppe Limongelli, Elena Biagini, Francesco Cappelli, Francesca Graziani, Emanuele Monda, Iacopo Olivotto, Vanda Parisi, Maurizio Pieroni, Marta Rubino, Serena Serratore, Gianfranco Sinagra, Ciro Indolfi, Pasquale Perrone Filardi

Aims: The Italian Fabry Disease Cardiovascular Registry (IFDCR) comprises 50 Italian centres with specific expertise in managing cardiovascular manifestations and complications of patients with Fabry disease (FD). The primary aim of the IFDCR is to examine and improve the clinical care and outcomes of patients with FD by addressing several knowledge gaps in the epidemiology, natural history, genotype-phenotype correlations, diagnosis, and management of this condition, with particular focus on cardiovascular manifestations and complications.

Methods and results: The IFDCR is an international, longitudinal, multicentre, non-interventional, observational study. Consecutive patients aged ≥2 years with a diagnosis of FD will be included in the study. The recruitment period consists of two parts: the retrospective enrolment period, from January 1981 to December 2023, and the prospective enrolment period, spanning from January 2024 to December 2031. The registry collects baseline and follow-up data, including the enrolment setting, patient demographics, family history, symptoms, clinical manifestations, electrocardiogram, cardiovascular imaging, laboratory assessment, medical therapy, genetic testing results, and outcomes.

Conclusions: The IFDCR is a national, multicentre, registry that includes patients with FD. It holds detailed and multiparametric data across the patient pathway and clinical manifestations, acting as a powerful tool for improving the quality of care and conducting high-impact research.

目的:意大利法布里病心血管注册中心(IFDCR)由 50 个意大利中心组成,这些中心在治疗法布里病(FD)患者的心血管表现和并发症方面具有专长。IFDCR 的主要目的是通过填补法布里病在流行病学、自然史、基因型与表型的相关性、诊断和管理方面的知识空白,检查并改善法布里病患者的临床护理和治疗效果,尤其关注心血管表现和并发症:IFDCR 是一项国际性、纵向、多中心、非干预性观察研究。被诊断为 FD 的年龄≥ 2 岁的连续患者将被纳入研究。招募期由两部分组成:回顾性招募期(1981 年 1 月至 2023 年 12 月)和前瞻性招募期(2024 年 1 月至 2031 年 12 月)。登记处收集基线和随访数据,包括登记环境、患者人口统计学、家族史、症状、临床表现、心电图、心血管成像、实验室评估、药物治疗、基因检测结果和结果:IFDCR是一个包括FD患者在内的全国性多中心登记系统。它拥有患者病程和临床表现的详细多参数数据,是提高医疗质量和开展高影响力研究的有力工具。
{"title":"The Italian Fabry Disease Cardiovascular Registry (IFDCR).","authors":"Giuseppe Limongelli, Elena Biagini, Francesco Cappelli, Francesca Graziani, Emanuele Monda, Iacopo Olivotto, Vanda Parisi, Maurizio Pieroni, Marta Rubino, Serena Serratore, Gianfranco Sinagra, Ciro Indolfi, Pasquale Perrone Filardi","doi":"10.1093/ehjqcco/qcae052","DOIUrl":"10.1093/ehjqcco/qcae052","url":null,"abstract":"<p><strong>Aims: </strong>The Italian Fabry Disease Cardiovascular Registry (IFDCR) comprises 50 Italian centres with specific expertise in managing cardiovascular manifestations and complications of patients with Fabry disease (FD). The primary aim of the IFDCR is to examine and improve the clinical care and outcomes of patients with FD by addressing several knowledge gaps in the epidemiology, natural history, genotype-phenotype correlations, diagnosis, and management of this condition, with particular focus on cardiovascular manifestations and complications.</p><p><strong>Methods and results: </strong>The IFDCR is an international, longitudinal, multicentre, non-interventional, observational study. Consecutive patients aged ≥2 years with a diagnosis of FD will be included in the study. The recruitment period consists of two parts: the retrospective enrolment period, from January 1981 to December 2023, and the prospective enrolment period, spanning from January 2024 to December 2031. The registry collects baseline and follow-up data, including the enrolment setting, patient demographics, family history, symptoms, clinical manifestations, electrocardiogram, cardiovascular imaging, laboratory assessment, medical therapy, genetic testing results, and outcomes.</p><p><strong>Conclusions: </strong>The IFDCR is a national, multicentre, registry that includes patients with FD. It holds detailed and multiparametric data across the patient pathway and clinical manifestations, acting as a powerful tool for improving the quality of care and conducting high-impact research.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Greenness Exposure and Mortality Risk in a Cardio-Oncologic Population. 绿化暴露与心脑肿瘤人群的死亡风险
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae079
Saar Ashri, Gali Cohen, Osnat Itzhaki Ben Zadok, Mika Moran, David M Broday, David M Steinberg, Lital Keinan-Boker, Guy Witberg, Tamir Bental, Lihi Golan, Itamar Shafran, Ran Kornowski, Yariv Gerber

Background and aims: Knowledge is lacking on the relationship between greenness and mortality in cancer survivors who experience coronary artery disease (CAD), a cardio-oncologic population. We aimed to investigate the association between residential greenness exposure and all-cause mortality in a cardio-oncologic population.

Methods: Cancer survivors undergoing percutaneous coronary intervention at the Rabin Medical Center in Israel between 2004 and 2014 were included in the study. Clinical data were collected from medical records during index hospitalization and from the Israeli National Cancer Registry. Residential greenness was estimated by the normalized difference vegetation index (NDVI), a satellite-based index derived from Landsat imagery at a 30-meter spatial resolution, with larger values indicating higher levels of vegetative density (ranging between -1 to 1). Mortality follow-up data were obtained through the end of 2021. Cox models were used to assess the hazard ratios (HRs) for all-cause mortality per 1SD increase in NDVI.

Results: Among 1,331 patients analyzed [mean (SD) age, 75.6 (10.2) years, 373 (28%) females], the mean (SD) NDVI within a 300-meter radius was 0.12 (0.03). During a median follow-up period of 12.0 (IQR 9.2-14.7) years, 883 (66%) participants died. After adjustment for potential confounding factors, including residential socioeconomic status, air pollution, and smoking, NDVI was inversely associated with mortality hazard [HR (95% CI) = 0.93 (0.86, 0.99); p=.042]. The association was stronger among individuals with more recently (<10 years) diagnosed cancer [HR (95% CI) = 0.89 (0.81, 0.98); p=.019].

Conclusion: In a cohort of cardio-oncologic patients, greenness was independently associated with lower mortality.

背景和目的:目前还缺乏关于冠状动脉疾病(CAD)癌症幸存者(心血管肿瘤人群)绿化与死亡率之间关系的知识。我们的目的是调查心血管肿瘤人群中住宅绿化暴露与全因死亡率之间的关系:研究对象包括 2004 年至 2014 年期间在以色列拉宾医疗中心接受经皮冠状动脉介入治疗的癌症幸存者。临床数据来自住院期间的医疗记录和以色列国家癌症登记处。住宅区绿化程度通过归一化差异植被指数(NDVI)进行估算,该指数基于陆地卫星图像,空间分辨率为 30 米,数值越大表示植被密度越高(介于-1 到 1 之间)。死亡率跟踪数据已收集至 2021 年底。采用 Cox 模型评估 NDVI 每增加 1SD 所导致的全因死亡率的危险比 (HR):在分析的 1331 名患者中(平均(标清)年龄为 75.6 (10.2) 岁,女性 373 (28%)),300 米半径范围内的 NDVI 平均(标清)值为 0.12 (0.03)。在 12.0 (IQR 9.2-14.7) 年的中位随访期内,883 名(66%)参与者死亡。在对潜在的混杂因素(包括居住地社会经济状况、空气污染和吸烟)进行调整后,NDVI 与死亡率成反比[HR (95% CI) = 0.93 (0.86, 0.99); p=0.042]。这种关联在近期死亡率较高的人群中更为明显:在一组心血管肿瘤患者中,绿色与较低的死亡率有独立联系。
{"title":"Greenness Exposure and Mortality Risk in a Cardio-Oncologic Population.","authors":"Saar Ashri, Gali Cohen, Osnat Itzhaki Ben Zadok, Mika Moran, David M Broday, David M Steinberg, Lital Keinan-Boker, Guy Witberg, Tamir Bental, Lihi Golan, Itamar Shafran, Ran Kornowski, Yariv Gerber","doi":"10.1093/ehjqcco/qcae079","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae079","url":null,"abstract":"<p><strong>Background and aims: </strong>Knowledge is lacking on the relationship between greenness and mortality in cancer survivors who experience coronary artery disease (CAD), a cardio-oncologic population. We aimed to investigate the association between residential greenness exposure and all-cause mortality in a cardio-oncologic population.</p><p><strong>Methods: </strong>Cancer survivors undergoing percutaneous coronary intervention at the Rabin Medical Center in Israel between 2004 and 2014 were included in the study. Clinical data were collected from medical records during index hospitalization and from the Israeli National Cancer Registry. Residential greenness was estimated by the normalized difference vegetation index (NDVI), a satellite-based index derived from Landsat imagery at a 30-meter spatial resolution, with larger values indicating higher levels of vegetative density (ranging between -1 to 1). Mortality follow-up data were obtained through the end of 2021. Cox models were used to assess the hazard ratios (HRs) for all-cause mortality per 1SD increase in NDVI.</p><p><strong>Results: </strong>Among 1,331 patients analyzed [mean (SD) age, 75.6 (10.2) years, 373 (28%) females], the mean (SD) NDVI within a 300-meter radius was 0.12 (0.03). During a median follow-up period of 12.0 (IQR 9.2-14.7) years, 883 (66%) participants died. After adjustment for potential confounding factors, including residential socioeconomic status, air pollution, and smoking, NDVI was inversely associated with mortality hazard [HR (95% CI) = 0.93 (0.86, 0.99); p=.042]. The association was stronger among individuals with more recently (<10 years) diagnosed cancer [HR (95% CI) = 0.89 (0.81, 0.98); p=.019].</p><p><strong>Conclusion: </strong>In a cohort of cardio-oncologic patients, greenness was independently associated with lower mortality.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cohort Profile: the prospective cohort study on the incidence of metabolic diseases and risk factors in Shunde, China (Speed-Shunde Cohort). 队列简介:中国顺德代谢性疾病发病率及危险因素前瞻性队列研究(硕贝德-顺德队列)。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-12 DOI: 10.1093/ehjqcco/qcae077
Heng Wan, Nanfang Yao, Jingli Yang, Guoqiu Huang, Siyang Liu, Xiao Wang, Xu Lin, Zhao Li, Lingling Liu, Aimin Yang, Lan Liu, Jie Shen

Aims: The objective of the prospective cohort study on the incidence of metabolic diseases and risk factors in Shunde (Speed-Shunde cohort) was to evaluate the incidence of cardiovascular-kidney-metabolic (CKM) syndrome and metabolic-associated multimorbidity, such as diabetes, hypertension, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease (MASLD) in Shunde, Foshan, Guangdong, China. Additionally, the study sought to identify the potential determinants that may impact the development of these conditions and the potential consequences that may result.

Methods and result: In the Speed-Shunde cohort, data were gathered via questionnaires, physical measurements, and laboratory analyses encompassing demographic data, behavioral tendencies, anthropometric assessments, controlled attenuation parameters and liver stiffness measurement utilizing vibration-controlled transient elastography (VCTE), as well as serum and urine detection (such as oral 75g glucose tolerance tests, hemoglobin A1c levels, lipid profiles, liver and renal function tests, urinary microalbumin and creatinine levels, etc.). The baseline data were gathered from October 2021 to September 2022 from over 10,000 Chinese community-based adults and the follow-up surveys would be conducted every two or three years. Blood and urine samples were obtained and stored for future omics data acquisition. Initial analyses revealed the prevalence and risk factors associated with metabolic-associated multimorbidity.

Conclusions: The Speed-Shunde Cohort study is a longitudinal community-based cohort with comprehensive CKM health and metabolic-associated multimorbidity assessment. It will provide valuable insights into these conditions' development, progression, and interrelationships, potentially informing future prevention and treatment strategies.

目的:"顺德地区代谢性疾病发病率及危险因素前瞻性队列研究"("硕贝德-顺德队列")旨在评估中国广东省佛山市顺德区心血管-肾脏-代谢综合征(CKM)和代谢相关多病(如糖尿病、高血压、血脂异常和代谢功能障碍相关性脂肪肝)的发病率。此外,该研究还试图找出可能影响这些疾病发展的潜在决定因素以及可能导致的潜在后果:硕贝德-顺德队列通过问卷调查、身体测量和实验室分析收集数据,包括人口统计学数据、行为倾向、人体测量评估、控制衰减参数、利用振动控制瞬态弹性成像(VCTE)测量肝脏硬度,以及血清和尿液检测(如口服 75g 葡萄糖耐量试验、血红蛋白 A1c 水平、血脂概况、肝肾功能检测、尿微量白蛋白和肌酐水平等)。基线数据于 2021 年 10 月至 2022 年 9 月期间从 10,000 多名中国社区成年人中收集,并将每隔两三年进行一次随访调查。采集的血液和尿液样本将被储存起来,以备将来获取全息数据。初步分析显示了代谢相关多病症的患病率和相关风险因素:斯比德-顺德队列研究是一项以社区为基础的纵向队列研究,对 CKM 健康和代谢相关多病症进行了全面评估。它将为了解这些疾病的发展、进程和相互关系提供宝贵的信息,并为未来的预防和治疗策略提供参考。
{"title":"Cohort Profile: the prospective cohort study on the incidence of metabolic diseases and risk factors in Shunde, China (Speed-Shunde Cohort).","authors":"Heng Wan, Nanfang Yao, Jingli Yang, Guoqiu Huang, Siyang Liu, Xiao Wang, Xu Lin, Zhao Li, Lingling Liu, Aimin Yang, Lan Liu, Jie Shen","doi":"10.1093/ehjqcco/qcae077","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae077","url":null,"abstract":"<p><strong>Aims: </strong>The objective of the prospective cohort study on the incidence of metabolic diseases and risk factors in Shunde (Speed-Shunde cohort) was to evaluate the incidence of cardiovascular-kidney-metabolic (CKM) syndrome and metabolic-associated multimorbidity, such as diabetes, hypertension, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease (MASLD) in Shunde, Foshan, Guangdong, China. Additionally, the study sought to identify the potential determinants that may impact the development of these conditions and the potential consequences that may result.</p><p><strong>Methods and result: </strong>In the Speed-Shunde cohort, data were gathered via questionnaires, physical measurements, and laboratory analyses encompassing demographic data, behavioral tendencies, anthropometric assessments, controlled attenuation parameters and liver stiffness measurement utilizing vibration-controlled transient elastography (VCTE), as well as serum and urine detection (such as oral 75g glucose tolerance tests, hemoglobin A1c levels, lipid profiles, liver and renal function tests, urinary microalbumin and creatinine levels, etc.). The baseline data were gathered from October 2021 to September 2022 from over 10,000 Chinese community-based adults and the follow-up surveys would be conducted every two or three years. Blood and urine samples were obtained and stored for future omics data acquisition. Initial analyses revealed the prevalence and risk factors associated with metabolic-associated multimorbidity.</p><p><strong>Conclusions: </strong>The Speed-Shunde Cohort study is a longitudinal community-based cohort with comprehensive CKM health and metabolic-associated multimorbidity assessment. It will provide valuable insights into these conditions' development, progression, and interrelationships, potentially informing future prevention and treatment strategies.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive risk management for hypertensive patients. 高血压患者的综合风险管理。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-12 DOI: 10.1093/ehjqcco/qcae078
Giacomo Frati, Giuseppe Biondi-Zoccai, Mariangela Peruzzi, Valentina Valenti
{"title":"Comprehensive risk management for hypertensive patients.","authors":"Giacomo Frati, Giuseppe Biondi-Zoccai, Mariangela Peruzzi, Valentina Valenti","doi":"10.1093/ehjqcco/qcae078","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae078","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the safety and efficacy of catheter ablation for atrial fibrillation in very elderly patients: insight from the national prospective registry study. 评估老年心房颤动导管消融术的安全性和有效性:国家前瞻性登记研究的启示。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-06 DOI: 10.1093/ehjqcco/qcae072
Koichi Inoue, Michikazu Nakai, Teiichi Yamane, Kengo Kusano, Seiji Takatsuki, Kazuhiro Satomi, Yoshitaka Iwanaga, Koshiro Kanaoka, Reina Tonegawa-Kuji, Yoko Sumita, Misa Takegami, Yoko M Nakao, Akihiko Nogami, Yoshihiro Miyamoto, Wataru Shimizu

Background and aims: This study evaluated the safety and efficacy of catheter ablation in treating atrial fibrillation (AF) among the elderly population.

Methods: A total of 170 017 AF ablation procedures prospectively enrolled from 482 facilities between 2017 and 2020 were analysed. They were stratified into six age groups, ranging from < 65 to ≥ 85 years, in 5-year increments. A cut-off of 80 years was set for dividing participants into two groups. The primary endpoints included procedure-related complications and 1-year arrhythmia recurrence after a 3-month blanking period.

Results: Patients ≥ 80 years constituted 7.2% of procedures in 2017, which significantly increased to 9.6% by 2020 (p < 0.001). This older group predominantly comprised women, with smaller stature and body mass index, a higher prevalence of paroxysmal AF, and a higher rate of initial ablation procedures. The overall complication rate was 2.8%, showing a positive correlation with age (p < 0.001), peaking at 4.3% for patients ≥ 85 years. Older age remained a significant independent risk factor for complications (odds ratio: 1.36 [1.24, 1.49], p < 0.001). Cardiac tamponade, ischemic stroke, and sick sinus syndrome were more common in the elderly. The recurrence rate in the total population was 16.0% and did not differ significantly between age groups (log-rank p = 0.473), remaining consistent even after adjusting for multiple variables.

Conclusions: Although age increases complication risk, recurrence rates remained steady across age groups, suggesting that AF ablation is a reasonable option for elderly individuals, contingent on careful patient selection for safety. (ClinicalTrials.gov: NCT03729232).

背景与目的本研究评估了导管消融术治疗老年人心房颤动(房颤)的安全性和有效性:分析了2017年至2020年期间482家医疗机构前瞻性登记的170 017例房颤消融术。这些患者被分为六个年龄组,从结果来看,≥80 岁的患者占 7.5%:2017 年,≥ 80 岁的患者占手术的 7.2%,到 2020 年,这一比例大幅上升至 9.6%(p 结论:虽然年龄会增加并发症风险,但复发率并不高:虽然年龄会增加并发症风险,但各年龄组的复发率保持稳定,这表明房颤消融术是老年人的合理选择,但必须谨慎选择患者以确保安全。(临床试验:NCT03729232)。
{"title":"Assessment of the safety and efficacy of catheter ablation for atrial fibrillation in very elderly patients: insight from the national prospective registry study.","authors":"Koichi Inoue, Michikazu Nakai, Teiichi Yamane, Kengo Kusano, Seiji Takatsuki, Kazuhiro Satomi, Yoshitaka Iwanaga, Koshiro Kanaoka, Reina Tonegawa-Kuji, Yoko Sumita, Misa Takegami, Yoko M Nakao, Akihiko Nogami, Yoshihiro Miyamoto, Wataru Shimizu","doi":"10.1093/ehjqcco/qcae072","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae072","url":null,"abstract":"<p><strong>Background and aims: </strong>This study evaluated the safety and efficacy of catheter ablation in treating atrial fibrillation (AF) among the elderly population.</p><p><strong>Methods: </strong>A total of 170 017 AF ablation procedures prospectively enrolled from 482 facilities between 2017 and 2020 were analysed. They were stratified into six age groups, ranging from < 65 to ≥ 85 years, in 5-year increments. A cut-off of 80 years was set for dividing participants into two groups. The primary endpoints included procedure-related complications and 1-year arrhythmia recurrence after a 3-month blanking period.</p><p><strong>Results: </strong>Patients ≥ 80 years constituted 7.2% of procedures in 2017, which significantly increased to 9.6% by 2020 (p < 0.001). This older group predominantly comprised women, with smaller stature and body mass index, a higher prevalence of paroxysmal AF, and a higher rate of initial ablation procedures. The overall complication rate was 2.8%, showing a positive correlation with age (p < 0.001), peaking at 4.3% for patients ≥ 85 years. Older age remained a significant independent risk factor for complications (odds ratio: 1.36 [1.24, 1.49], p < 0.001). Cardiac tamponade, ischemic stroke, and sick sinus syndrome were more common in the elderly. The recurrence rate in the total population was 16.0% and did not differ significantly between age groups (log-rank p = 0.473), remaining consistent even after adjusting for multiple variables.</p><p><strong>Conclusions: </strong>Although age increases complication risk, recurrence rates remained steady across age groups, suggesting that AF ablation is a reasonable option for elderly individuals, contingent on careful patient selection for safety. (ClinicalTrials.gov: NCT03729232).</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A decade of follow-up: atrial fibrillation, pulmonary pressure, and the progression of tricuspid regurgitation. 十年随访:心房颤动、肺动脉压力和三尖瓣反流的进展。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-31 DOI: 10.1093/ehjqcco/qcae075
Ranel Loutati, Asaf Katz, Amit Segev, Rafael Kuperstein, Avi Sabbag, Elad Maor

Background and aims: Long-term data on atrial fibrillation (AF) impact on tricuspid regurgitation (TR) progression and its relation to pulmonary pressure are scant. We investigated this association in a study spanning over a decade.

Methods: Adults with echocardiographic evaluation before 2014, free of significant TR, were included. Patients were dichotomized by baseline AF, followed by stratification according to systolic pulmonary artery pressure (sPAP). The development of new significant TR and its impact on mortality were studied.

Results: Study population included 21 502 patients (median age 65, 40% female), 13% had baseline AF. During a median follow-up of 12 years, 11% developed significant TR. Compared with patients free of AF, patients with baseline AF were 3.5 and 1.3 times more likely to develop significant TR in a univariate and multivariate models, respectively (95% CI 3.27-3.91, 1.18-1.44, p < 0.001 for both). The risk of TR progression was higher in patients with permanent AF and those treated with rate control strategy (HR 1.95 and 2.01, respectively; p < 0.001 for both). The association of AF with TR progression was sPAP-related, being more pronounced among patients with normal sPAP than among those with elevated sPAP (HR 1.5 vs. 1.18; p for interaction < 0.001). TR progression was independently linked to a two-fold higher mortality risk, consistent regardless of baseline AF (p < 0.001).

Conclusions: AF is an independent predictor of TR progression, especially in patients with normal sPAP. Subsequent research on strategies to prevent TR progression in this patient population are warranted.This analysis investigated the association of AF with TR progression, and the interaction of pulmonary arterial pressure with this link. Among patients with AF (Left), progression to significant TR is highly prevalent, with higher risk among patients with permanent AF and lower risk in those treated with rhythm control strategy. Pulmonary arterial pressure interacts with this association (Right), such that among patients with normal sPAP, the link between AF and TR progression is stronger, suggesting that the importance of proactive AF management in this sugroup of patients. TR has important implications on mortality, regardless of AF status (Middle).AF = Atrial Fibrillation; A-STR = Atrial Secondary TR; CIED = cardiac implantable electronic device; TR = Tricuspid Regurgitation; V-STR = Ventricular Secondary TR.

背景和目的:有关心房颤动(AF)对三尖瓣反流(TR)进展的影响及其与肺动脉压力关系的长期数据很少。我们在一项跨越十年的研究中调查了这种关联:方法:纳入 2014 年之前接受超声心动图评估、无明显三尖瓣反流的成年人。根据基线房颤对患者进行二分,然后根据肺动脉收缩压(sPAP)进行分层。研究了新出现的明显TR及其对死亡率的影响:研究对象包括 21 502 名患者(中位年龄 65 岁,40% 为女性),其中 13% 有基线房颤。在12年的中位随访期间,11%的患者出现了明显的TR。与无房颤的患者相比,在单变量和多变量模型中,基线房颤患者发生明显TR的几率分别是无房颤患者的3.5倍和1.3倍(95% CI 3.27-3.91, 1.18-1.44, p 结论:房颤是发生明显TR的独立预测因素:房颤是 TR 进展的独立预测因素,尤其是在 sPAP 正常的患者中。本分析调查了房颤与 TR 进展的关系,以及肺动脉压与这一关系的相互作用。在房颤患者(左侧)中,进展为明显TR的情况非常普遍,永久性房颤患者的风险较高,而接受节律控制策略治疗的患者风险较低。肺动脉压与这一关联相互影响(右图),因此在 sPAP 正常的患者中,房颤与 TR 进展之间的关联更强,这表明对这部分患者进行积极的房颤管理非常重要。无论房颤状态如何,TR 对死亡率都有重要影响(中)。AF = 心房颤动;A-STR = 心房继发性 TR;CIED = 心脏植入式电子装置;TR = 三尖瓣反流;V-STR = 心室继发性 TR。
{"title":"A decade of follow-up: atrial fibrillation, pulmonary pressure, and the progression of tricuspid regurgitation.","authors":"Ranel Loutati, Asaf Katz, Amit Segev, Rafael Kuperstein, Avi Sabbag, Elad Maor","doi":"10.1093/ehjqcco/qcae075","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae075","url":null,"abstract":"<p><strong>Background and aims: </strong>Long-term data on atrial fibrillation (AF) impact on tricuspid regurgitation (TR) progression and its relation to pulmonary pressure are scant. We investigated this association in a study spanning over a decade.</p><p><strong>Methods: </strong>Adults with echocardiographic evaluation before 2014, free of significant TR, were included. Patients were dichotomized by baseline AF, followed by stratification according to systolic pulmonary artery pressure (sPAP). The development of new significant TR and its impact on mortality were studied.</p><p><strong>Results: </strong>Study population included 21 502 patients (median age 65, 40% female), 13% had baseline AF. During a median follow-up of 12 years, 11% developed significant TR. Compared with patients free of AF, patients with baseline AF were 3.5 and 1.3 times more likely to develop significant TR in a univariate and multivariate models, respectively (95% CI 3.27-3.91, 1.18-1.44, p < 0.001 for both). The risk of TR progression was higher in patients with permanent AF and those treated with rate control strategy (HR 1.95 and 2.01, respectively; p < 0.001 for both). The association of AF with TR progression was sPAP-related, being more pronounced among patients with normal sPAP than among those with elevated sPAP (HR 1.5 vs. 1.18; p for interaction < 0.001). TR progression was independently linked to a two-fold higher mortality risk, consistent regardless of baseline AF (p < 0.001).</p><p><strong>Conclusions: </strong>AF is an independent predictor of TR progression, especially in patients with normal sPAP. Subsequent research on strategies to prevent TR progression in this patient population are warranted.This analysis investigated the association of AF with TR progression, and the interaction of pulmonary arterial pressure with this link. Among patients with AF (Left), progression to significant TR is highly prevalent, with higher risk among patients with permanent AF and lower risk in those treated with rhythm control strategy. Pulmonary arterial pressure interacts with this association (Right), such that among patients with normal sPAP, the link between AF and TR progression is stronger, suggesting that the importance of proactive AF management in this sugroup of patients. TR has important implications on mortality, regardless of AF status (Middle).AF = Atrial Fibrillation; A-STR = Atrial Secondary TR; CIED = cardiac implantable electronic device; TR = Tricuspid Regurgitation; V-STR = Ventricular Secondary TR.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Heart Journal - Quality of Care and Clinical Outcomes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1